Satavaptan in the Prevention of Ascites Recurrence: a Double-blind, Randomised, Parallel-group Comparison of Satavaptan at 5 to 10 mg Daily Versus Placebo With Concomitant Diuretics in Patients With Recurrent Ascites Due to Cirrhosis of the Liver
Latest Information Update: 04 Apr 2022
At a glance
- Drugs Satavaptan (Primary)
- Indications Ascites; Liver cirrhosis
- Focus Therapeutic Use
- Acronyms SPARe-1
- Sponsors Sanofi
Most Recent Events
- 03 Apr 2022 This trial has been completed in Netherland, according to European Clinical Trials Database record.
- 04 Sep 2021 This trial has been completed in Spain, according to European Clinical Trials Database.
- 30 Jun 2021 Results of post-hoc analysis of three studies (NCT00358878, NCT00359437 and NCT00366795) published in the Digestive Diseases and Sciences.